WuXi Biologics (Cayman) Inc 2017 AR2
The report highlights WuXi Biologics' significant operational and financial growth in 2017, including a 63.7% increase in revenue to RMB1,618.8 million. Key achievements include the successful U.S. FDA Pre-License Inspection of its cGMP manufacturing facilities in Wuxi, making it the first FDA-approved biologics commercial manufacturing facility in China. Additionally, the company initiated commercial operations at the world's largest biologics manufacturing facility using only single-use bioreactors. On the sustainability front, the company obtained the Intellectual Property Management System Certification and implemented several environmental initiatives, such as a concentrated water reuse project at its Wuxi site.
Company: WuXi Biologics (Cayman) Inc
Sector: Health Care
Country: China
Year: 2017
Type: AR2
Pages: 187
WuXi Biologics (Cayman) Inc
Annual Report
The report highlights WuXi Biologics' significant operational and financial growth in 2017, including a 63.7% increase in revenue to RMB1,618.8 million. Key achievements include the successful U.S. FDA Pre-License Inspection of its cGMP manufacturing facilities in Wuxi, making it the first FDA-approved biologics commercial manufacturing facility in China. Additionally, the company initiated commercial operations at the world's largest biologics manufacturing facility using only single-use bioreactors. On the sustainability front, the company obtained the Intellectual Property Management System Certification and implemented several environmental initiatives, such as a concentrated water reuse project at its Wuxi site.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Employees